OBJECTIVE: This trial evaluated the effect of methylphenidate transdermal system (MTS) on the full spectrum of adult symptoms (attention-disorganization, hyperactivity-impulsivity, emotional dysregulation [ED], and oppositional-defiant disorder [ODD]) found in this disorder. METHOD: This placebo-controlled, double-blind, flexible-dose, crossover trial employed the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) and Connor's Adult ADHD Rating Scale (CAARS) and two measures of adult ODD. Treatment responses of all participants and four subgroups (ADHDalone, ADHD + ED, ADHD + ODD, and ADHD + ED + ODD) were assessed. RESULTS: Around 23% of baseline participants were ADHD alone, 31% were ADHD + ED, 10% were ADHD + ODD, and 36% were ADHD + ED + ODD. There was a significant treatment effect for all symptom areas and all four subgroups. MTS was associated with significantly more adverse events, especially dermatologic side effects. CONCLUSIONS:MTS was effective in treating adult ADHD. This clinical trial included numerous participants meeting criteria for ED and ODD. All ADHD symptoms responded positively to treatment with MTS.
RCT Entities:
OBJECTIVE: This trial evaluated the effect of methylphenidate transdermal system (MTS) on the full spectrum of adult symptoms (attention-disorganization, hyperactivity-impulsivity, emotional dysregulation [ED], and oppositional-defiant disorder [ODD]) found in this disorder. METHOD: This placebo-controlled, double-blind, flexible-dose, crossover trial employed the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) and Connor's Adult ADHD Rating Scale (CAARS) and two measures of adult ODD. Treatment responses of all participants and four subgroups (ADHDalone, ADHD + ED, ADHD + ODD, and ADHD + ED + ODD) were assessed. RESULTS: Around 23% of baseline participants were ADHD alone, 31% were ADHD + ED, 10% were ADHD + ODD, and 36% were ADHD + ED + ODD. There was a significant treatment effect for all symptom areas and all four subgroups. MTS was associated with significantly more adverse events, especially dermatologic side effects. CONCLUSIONS:MTS was effective in treating adult ADHD. This clinical trial included numerous participants meeting criteria for ED and ODD. All ADHD symptoms responded positively to treatment with MTS.
Authors: James G Waxmonsky; D A Waschbusch; D E Babinski; H H Humphrey; A Alfonso; K I Crum; M Bernstein; J Slavec; J N Augustus; W E Pelham Journal: CNS Drugs Date: 2014-07 Impact factor: 5.749
Authors: Gholson J Lyon; Tao Jiang; Richard Van Wijk; Wei Wang; Paul Mark Bodily; Jinchuan Xing; Lifeng Tian; Reid J Robison; Mark Clement; Yang Lin; Peng Zhang; Ying Liu; Barry Moore; Joseph T Glessner; Josephine Elia; Fred Reimherr; Wouter W van Solinge; Mark Yandell; Hakon Hakonarson; Jun Wang; William Evan Johnson; Zhi Wei; Kai Wang Journal: Discov Med Date: 2011-07 Impact factor: 2.970
Authors: Wolfgang Retz; Michael Rösler; Claudia Ose; André Scherag; Barbara Alm; Alexandra Philipsen; Roland Fischer; Richard Ammer Journal: World J Biol Psychiatry Date: 2010-12-14 Impact factor: 4.132